Related Articles
Rapamycin provides a therapeutic option through inhibition of mTOR signaling in chronic myelogenous leukemia
Rapamycin enhanced the antitumor effects of doxorubicin in myelogenous leukemia K562 cells by downregulating the mTOR/p70S6K pathway
Tubeimoside I induces autophagy in HepG2 cells by activating the AMP‑activated protein kinase signaling pathway
Dual PI3K/mTOR inhibitor NVP‑BEZ235 decreases the proliferation of doxorubicin‑resistant K562 cells
Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation